Testosterone biosynthesis pathway

The **testosterone biosynthesis pathway** is a multi-step biochemical process occurring primarily in Leydig cells of the testes, responsible for the production of the androgen testosterone from cholesterol. The canonical pathway in humans is divided into the Δ4 and Δ5 pathways, involving several steroidogenic enzymes including CYP17A1 (17α-hydroxylase and 17,20-lyase activities), HSD3B1/2, and HSD17B3. These enzymes sequentially convert cholesterol to pregnenolone, then to DHEA and androstenedione, and finally to testosterone, often regulated by luteinizing hormone. Disruptions in this pathway have implications for disorders such as male hypogonadism and are relevant to cancer biology owing to testosterone's role in androgen-signaling tumors[1][2][4][7]. **Important note:** This entry is flagged as *incorrect* for a molecular target list because the "Testosterone biosynthesis pathway" does not refer to a single druggable protein target, receptor, or enzyme, but to an entire metabolic pathway composed of many enzyme targets (such as CYP17A1, HSD3B1/2, HSD17B3, etc.). Drugs that influence testosterone biosynthesis act at specific enzymes within this pathway rather than on the pathway itself[2][4][6].

Other names

Androgen biosynthesis pathwaySteroid hormone biosynthesis pathway

Null for the pathway itself (Mechanism is collective: enzyme inhibition or stimulation at specific steps)